Ozempic, Mounjaro, and Wegovy: Storage, Side Effects, and What to Know

What Are GLP-1 Medications? A Plain-Language Explanation

Ozempic (semaglutide), Mounjaro (tirzepatide), and Wegovy (semaglutide) belong to a class of injectable medications called GLP-1 receptor agonists — and in Mounjaro's case, a dual GIP/GLP-1 agonist. GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone released from the gut after eating that signals the pancreas to produce insulin, slows gastric emptying, and reduces appetite signals in the brain.

These medications mimic or enhance that natural hormone response. Originally developed to treat type 2 diabetes, several have since received FDA approval for chronic weight management. As of 2024, over 9 million Americans have been prescribed one of these medications, and global demand has caused recurring supply shortages. Understanding how to store, handle, and use them correctly is essential — because improper storage can render an expensive, hard-to-get medication completely ineffective.

• Ozempic (semaglutide): FDA-approved for type 2 diabetes; off-label use for weight loss is common
• Wegovy (semaglutide): FDA-approved for chronic weight management (higher dose than Ozempic)
• Mounjaro (tirzepatide): FDA-approved for type 2 diabetes; its sister drug Zepbound is approved for obesity
• Zepbound (tirzepatide): FDA-approved for weight management; same molecule as Mounjaro

GLP-1 Medication Storage Requirements: The Complete Guide

Refrigerator Storage (Unopened Pens)

All GLP-1 injectable pens must be kept refrigerated before first use. The required temperature range is 36°F to 46°F (2°C to 8°C) — the standard range for a home refrigerator. Store pens in the original carton to protect them from light, and keep them away from the freezer compartment or refrigerator walls, which can cause freezing. Never freeze these medications — freezing permanently damages the molecular structure and makes them ineffective. A frozen pen must be discarded.

Room Temperature Storage (In-Use Pens)

Once you begin using a pen — even if you haven't injected yet — the clock starts. Here are the approved room-temperature windows for each medication:

Source: FDA prescribing information for each medication. Always follow the most current labeling provided with your prescription.

What Happens If Your Medication Gets Too Hot?

Heat degrades the protein structure of GLP-1 medications. Exposure above the maximum temperature — even briefly on a hot day — can reduce potency or render the pen completely inactive. The dangerous part: the medication will still look perfectly normal. It won't change color, become cloudy, or smell different. You would have no way of knowing it had degraded — until you noticed your blood sugar not responding or your appetite returning unexpectedly.

This is why passive cooling solutions (ice packs, zip-lock bags) are risky: they can freeze the medication or provide inconsistent temperatures. A purpose-built medication cooler is the safest solution.

Signs Your GLP-1 Medication Has Gone Bad

While heat degradation is invisible, there are some physical signs that indicate a pen should be discarded:

• The solution is cloudy or discolored (Ozempic and Mounjaro should be clear and colorless)
• Visible particles or floaters in the solution
• The pen was frozen (ice crystals visible, or frozen solid)
• The pen was exposed to temperatures above the stated maximum
• The pen has been in use beyond its approved room-temperature window
• The expiration date has passed

When in doubt, contact your pharmacist. Given that a single monthly supply of Ozempic can cost $900+ without insurance, it is worth the phone call.

Traveling With Ozempic, Mounjaro, and Wegovy

TSA Rules for Injectable Medications

The Transportation Security Administration (TSA) explicitly accommodates passengers traveling with injectable medications. Here is what you need to know:

• Injectable medications and their pens are exempt from the 3.4 oz (100ml) liquid rule
• You may carry your medication in your carry-on or checked baggage — carry-on is strongly recommended to avoid temperature extremes in cargo holds
• Inform TSA officers at the checkpoint that you are carrying injectable medication
• Pens may go through X-ray screening without harm
• Keep medications in original labeled packaging when possible
• A letter from your prescribing physician is not required by TSA but can be helpful, especially for international travel

International Travel With GLP-1 Medications

Rules vary by country. Many nations require a physician letter or prescription documentation to import injectable medications. Research the specific requirements of your destination country before traveling. The International Diabetes Federation and your country's embassy website are reliable starting points. Some countries — including Japan and several others — have strict rules about importing medications without prior authorization.

Keeping Your Medication Cold While Traveling

This is where most travelers struggle. Traditional approaches — hotel mini-fridges, ice packs, insulated pouches — are unreliable. Hotel mini-fridges often run too cold and can freeze medications. Ice packs melt unpredictably and create condensation. An active, purpose-built solution is the gold standard for medication travelers.

The VIVI CAP Insulin & GLP-1 Pen Cooler, available at mdsdiabetes.com, was specifically designed for this problem. It uses passive thermoelectric technology — no batteries, no ice, no charging required — to maintain a safe temperature for your pen regardless of the ambient environment. It caps directly onto Ozempic, Wegovy, Mounjaro, and Zepbound pens. It is TSA approved, airline-safe, and compact enough for a purse or pocket.

Pen Injection Technique: Step-by-Step

Proper injection technique ensures the medication is absorbed correctly and minimizes discomfort and side effects.

Before You Inject

1. Wash hands thoroughly with soap and water
2. Remove the pen from the refrigerator 15–30 minutes before injecting — injecting cold medication can cause discomfort
3. Inspect the solution: it should be clear and colorless
4. Attach a new needle (for multi-dose pens like Ozempic)
5. Prime the pen according to the manufacturer's instructions for first use

Injection Sites

GLP-1 medications are injected subcutaneously (into the fat layer beneath the skin). Approved injection sites include:

• Abdomen (at least 2 inches from the navel)
• Upper thigh (front or outer)
• Upper arm (outer area)

Rotate injection sites with each dose to prevent lipodystrophy (hardening or dimpling of the fat tissue), which can affect drug absorption. Keep a simple log if needed.

The Injection

1. Clean the skin with an alcohol swab and allow to dry completely
2. Pinch the skin lightly (optional but helpful for leaner individuals)
3. Insert the needle at a 90-degree angle
4. Press and hold the injection button — hold for the full count indicated (usually 5–10 seconds) to ensure complete dose delivery
5. Remove the needle, then release the skin pinch
6. Do not rub the injection site
7. Carefully recap and dispose of the needle in a sharps container

Side Effects of GLP-1 Medications

Common Side Effects

The majority of side effects are gastrointestinal and tend to be most pronounced when starting the medication or after a dose increase. They typically improve over several weeks as the body adjusts.

• Nausea — the most commonly reported side effect; affects up to 44% of Wegovy users in clinical trials
• Vomiting
• Diarrhea
• Constipation
• Stomach pain or bloating
• Decreased appetite (often the desired effect for weight management users)
• Heartburn or acid reflux
• Fatigue, particularly early in treatment

Serious Side Effects (Seek Medical Attention)

• Pancreatitis: Severe abdominal pain radiating to the back, with or without vomiting — stop medication and seek emergency care
• Gallbladder disease: GLP-1 medications increase the risk of gallstones; symptoms include sudden severe pain in the upper right abdomen
• Kidney problems: Dehydration from nausea/vomiting can worsen kidney function
• Diabetic retinopathy: Rapid improvement in blood sugar has been associated with worsening of diabetic eye disease in some patients
• Thyroid tumors: Based on animal studies, GLP-1 medications carry a black box warning for thyroid C-cell tumors; clinical significance in humans is uncertain but the medications are contraindicated in those with a personal or family history of medullary thyroid carcinoma
• Hypoglycemia: More of a risk when combined with insulin or sulfonylureas

"Ozempic Face" and Muscle Loss

Rapid weight loss — particularly on higher-dose medications like Wegovy — can cause facial volume loss (nicknamed "Ozempic face") and muscle mass reduction. Adequate protein intake (typically 1.2–1.6g per kg of body weight) and resistance exercise can help preserve lean muscle during weight loss on these medications.

Who Should Not Take GLP-1 Medications

These medications are contraindicated in the following populations:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Pregnancy — GLP-1 medications should be discontinued at least 2 months before planned pregnancy (semaglutide) or per physician guidance
• Breastfeeding
• Known hypersensitivity to the active ingredient
• Type 1 diabetes (not approved; risk of DKA)
• History of severe pancreatitis (use with caution)

Insurance Coverage and Cost

Without Insurance

GLP-1 medications are among the most expensive drugs in the United States. Without insurance or manufacturer savings programs, monthly costs are approximately:

• Ozempic: $900–$1,000 per month
• Wegovy: $1,300–$1,400 per month
• Mounjaro: $1,000–$1,100 per month
• Zepbound: $1,000–$1,100 per month

Manufacturer Savings Programs

Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound) both offer savings cards for commercially insured patients. Eligible patients may pay as little as $25–$150/month with a manufacturer coupon. These programs generally do not apply to Medicare or Medicaid beneficiaries.

Insurance Coverage

Coverage varies significantly by plan and indication. Ozempic and Mounjaro (prescribed for diabetes) have broader insurance coverage than Wegovy and Zepbound (prescribed for weight loss). As of 2024, Medicare Part D does not cover medications prescribed exclusively for weight loss, though this may change with pending legislation. Always confirm your specific coverage with your insurance provider and pharmacy before filling your prescription.

Product Recommendation: VIVI CAP Insulin & GLP-1 Pen Cooler

Frequently Asked Questions